{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:26Z","timestamp":1772166386113,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the China International Food and Medicine Exchange Center of NMPA Commissioned Research Project \u201cInternational Publicity on the Safety of Traditional Chinese Medicine\u201d","award":["Z0531"],"award-info":[{"award-number":["Z0531"]}]},{"name":"Fundamental Research Funds for the Central Public Welfare Research Institutes","award":["Z0546"],"award-info":[{"award-number":["Z0546"]}]},{"name":"Scientific Research Innovation Team Project of China Academy of Chinese Medical Sciences","award":["PY1303"],"award-info":[{"award-number":["PY1303"]}]},{"name":"Research Project of Postgraduate Education and Teaching Reform of China Academy of Chinese Medical Sciences","award":["JG201703"],"award-info":[{"award-number":["JG201703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3539-5","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T09:03:00Z","timestamp":1563526980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6518-622X","authenticated-orcid":false,"given":"Jian","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-wu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-yi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-xi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-tong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-he","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-hui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"issue":"1","key":"3539_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"B Foxman","year":"2014","unstructured":"Foxman B. Urinary tract infection syndromes occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin N Am. 2014;28(1):1\u201313. \n                    https:\/\/doi.org\/10.1016\/j.idc.2013.09.003\n                    \n                  .","journal-title":"Infect Dis Clin N Am"},{"issue":"2","key":"3539_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1067\/mda.2003.7","volume":"49","author":"B Foxman","year":"2003","unstructured":"Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dm Disease-a-Month. 2003;49(2):53\u201370. \n                    https:\/\/doi.org\/10.1067\/mda.2003.7\n                    \n                  .","journal-title":"Dm Disease-a-Month"},{"key":"3539_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.biopha.2017.08.006","volume":"94","author":"S Khoshnood","year":"2017","unstructured":"Khoshnood S, Heidary M, Mirnejad R, et al. Drug-resistant gram-negative uropathogens: A review. Biomed Pharmacother. 2017;94:982\u201394. \n                    https:\/\/doi.org\/10.1016\/j.biopha.2017.08.006\n                    \n                  .","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3539_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1001\/jama.2018.2089","volume":"319","author":"C El Bcheraoui","year":"2018","unstructured":"El Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and patterns of differences in infectious disease mortality among US counties, 1980\u20132014. JAMA. 2018;319(12):1248\u201360. \n                    https:\/\/doi.org\/10.1001\/jama.2018.2089\n                    \n                  .","journal-title":"JAMA."},{"issue":"2","key":"3539_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","volume":"129","author":"MS Bader","year":"2017","unstructured":"Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242\u201358. \n                    https:\/\/doi.org\/10.1080\/00325481.2017.1246055\n                    \n                  .","journal-title":"Postgrad Med"},{"issue":"22","key":"3539_CR6","first-page":"103","volume":"20","author":"YX Peng","year":"2014","unstructured":"Peng YX, Liu XQ, Wen LL, et al. Antibacterial activities of five Chinese medicines of Rhei Radiset Rhizoma and their chemical constituents against multidrug-resistant clinical bacteria isolates. Chinese J Exp Tradit Med Formulae. 2014;20(22):103\u20137.","journal-title":"Chinese J Exp Tradit Med Formulae"},{"issue":"11","key":"3539_CR7","first-page":"16","volume":"25","author":"DY Li","year":"2017","unstructured":"Li DY, Hou Y, Zhang KY, et al. Research progress on mechanism of anti-drug resistance of traditional Chinese medicine. China Med Eng. 2017;25(11):16\u20139.","journal-title":"China Med Eng"},{"issue":"08","key":"3539_CR8","first-page":"1148","volume":"16","author":"X Hou","year":"2016","unstructured":"Hou X, Wang LX. Research progress of Sanjin tablets. Eval Anal Drug Chin Hosp. 2016;16(08):1148\u201351.","journal-title":"Eval Anal Drug Chin Hosp"},{"issue":"5","key":"3539_CR9","first-page":"447","volume":"50","author":"JC Yi","year":"2015","unstructured":"Yi JC. Clinical observation of levofloxacin and Sanjin tablets in the treatment of urinary tract infection. JiangXi Med J. 2015;50(5):447\u20138.","journal-title":"JiangXi Med J"},{"issue":"30","key":"3539_CR10","first-page":"169","volume":"17","author":"XL Dong","year":"2017","unstructured":"Dong XL. Clinical efficacy and safety of Sanjin tablets combined with levofloxacin tablet in the treatment of urinary tract infection. The World\u2019s Latest Medical Information Abstracts. 2017;17(30):169\u201370.","journal-title":"The World\u2019s Latest Medical Information Abstracts"},{"issue":"9","key":"3539_CR11","first-page":"724","volume":"23","author":"HY Zheng","year":"2013","unstructured":"Zheng HY, Hu JG. Efficacy of Sanjin tablets combined with gatifloxacin in the treatment of acute simple lower urinary tract infection [J]. Zhejiang J Integr Tradit Chin West Med. 2013;23(9):724\u20136.","journal-title":"Zhejiang J Integr Tradit Chin West Med"},{"key":"3539_CR12","doi-asserted-by":"publisher","first-page":"789809","DOI":"10.1155\/2015\/789809","volume":"2015","author":"J Meng","year":"2015","unstructured":"Meng J, Zou Z, Lu C, et al. Identification and characterization of bioactive compounds targeting uropathogenic Escherichia coli from Sanjin tablets. J Chem. 2015;2015:789809. \n                    https:\/\/doi.org\/10.1155\/2015\/789809\n                    \n                  .","journal-title":"J Chem"},{"issue":"4","key":"3539_CR13","first-page":"1012","volume":"27","author":"X Pu","year":"2016","unstructured":"Pu X, Zhang LY, Zhang JH. A systematic review of Sanjin tablets in the treatment of simple urinary tract infection: a randomized controlled trial. Lishizhen Medicine and Materia Medica Research. 2016;27(4):1012\u20134.","journal-title":"Lishizhen Medicine and Materia Medica Research"},{"issue":"2","key":"3539_CR14","first-page":"303","volume":"30","author":"WH Li","year":"2012","unstructured":"Li WH, Zhu WT, Han L, et al. Pharmacoeconomic analysis of two integrated traditional and western treatment formulas of lower urinary tract infection. Chin Arch Tradit Chin Med. 2012;30(2):303\u20135.","journal-title":"Chin Arch Tradit Chin Med"},{"issue":"4","key":"3539_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","volume":"89","author":"PM Hawkey","year":"2015","unstructured":"Hawkey PM. Multidrug-resistant Gram-negative bacteria: a product of globalization. J Hosp Infect. 2015;89(4):241\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jhin.2015.01.008\n                    \n                  .","journal-title":"J Hosp Infect"},{"issue":"6","key":"3539_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1517\/17460441.2015.1048219","volume":"10","author":"R Penchovsky","year":"2015","unstructured":"Penchovsky R, Traykovska M. Designing drugs that overcome antibacterial resistance: where do we stand and what should we do? Expert Opin Drug Discovery. 2015;10(6):631\u201350. \n                    https:\/\/doi.org\/10.1517\/17460441.2015.1048219\n                    \n                  .","journal-title":"Expert Opin Drug Discovery"},{"issue":"20","key":"3539_CR17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191\u20134. \n                    https:\/\/doi.org\/10.1001\/jama.2013.281053\n                    \n                  .","journal-title":"JAMA."},{"key":"3539_CR18","unstructured":"National Medical Products Administration. Good Clinical Practice of Pharmaceutical Products. 2003-8-6. \n                    http:\/\/samr.cfda.gov.cn\/WS01\/CL0053\/24473.html\n                    \n                  ."},{"issue":"13","key":"3539_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1001\/jama.292.13.1593","volume":"292","author":"J Flory","year":"2004","unstructured":"Flory J, Emanuel E. Interventions to improve research participants\u2019 understanding in informed consent for research - A systematic review. JAMA. 2004;292(13):1593\u2013601. \n                    https:\/\/doi.org\/10.1001\/jama.292.13.1593\n                    \n                  .","journal-title":"JAMA."},{"issue":"5","key":"3539_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s1470-2045(08)70128-1","volume":"9","author":"M Jefford","year":"2008","unstructured":"Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol. 2008;9(5):485\u201393. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(08)70128-1\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"8","key":"3539_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1086\/592068","volume":"47","author":"MJ DiNubile","year":"2008","unstructured":"DiNubile MJ. Double-blind active-control trials: Beware the comparator you keep. Clin Infect Dis. 2008;47(8):1064\u20137. \n                    https:\/\/doi.org\/10.1086\/592068\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"7303","key":"3539_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","volume":"323","author":"P Juni","year":"2001","unstructured":"Juni P, Altman DG, Egger M. Systematic reviews in health care-Assessing the quality of controlled clinical trials. Br Med J. 2001;323(7303):42\u20136. \n                    https:\/\/doi.org\/10.1136\/bmj.323.7303.42\n                    \n                  .","journal-title":"Br Med J"},{"issue":"3","key":"3539_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, et al. SPIRIT 2013 statement: defining standard protocol items forclinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"3539_CR24","doi-asserted-by":"publisher","first-page":"c1432","DOI":"10.1136\/bmj.c1432","volume":"340","author":"G Antes","year":"2010","unstructured":"Antes G. The new CONSORT statement. BMJ. 2010;340:c1432.","journal-title":"BMJ."},{"issue":"12","key":"3539_CR25","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.4103\/0366-6999.216401","volume":"32","author":"H Liu","year":"2017","unstructured":"Liu H, Xie JX, Xu ZS. Clinical study of Sanjin pills to acute simple bacterial lower urinary tract infection based on the contrast of levofloxacin tablets. Acta Chinese Med. 2017;32(12):2489\u201392.","journal-title":"Acta Chinese Med"},{"key":"3539_CR26","volume-title":"Guidelines for the diagnosis and treatment of Urological Diseases in China (2014 ed)","author":"YQ Na","year":"2013","unstructured":"Na YQ, Sun G, Ye ZQ, et al. Guidelines for the diagnosis and treatment of Urological Diseases in China (2014 ed). Beijing: People\u2019s Medical Publishing House; 2013."},{"key":"3539_CR27","first-page":"25","volume":"05","author":"HX Wu","year":"1998","unstructured":"Wu HX. The National Standard Clinic Terminology of Traditional Chinese Medical Diagnosis and Treatment Was Released and Implemented. Chin J Inform Tradit Chin Med. 1998;05:25.","journal-title":"Chin J Inform Tradit Chin Med"},{"key":"3539_CR28","volume-title":"Internal Medicine of Traditional Chinese Medicine","author":"DL Tian","year":"2005","unstructured":"Tian DL. Internal Medicine of Traditional Chinese Medicine. Beijing: Chinese Medicine Press; 2005."},{"issue":"8","key":"3539_CR29","first-page":"712","volume":"16","author":"CB Jiang","year":"2015","unstructured":"Jiang CB, Song YL, Ren Y, et al. Clinical Observation on the Effect of Jiawei Zishen Tongguan Decoction in Treating Stranguria of Kidney Deficiency and Dampness-Heat Syndrome. Chin J Integr Tradit West Nephrol. 2015;16(8):712\u20134.","journal-title":"Chin J Integr Tradit West Nephrol"},{"issue":"12","key":"3539_CR30","first-page":"2527","volume":"16","author":"SY Yan","year":"2014","unstructured":"Yan SY, He LY, Liu BY. How to Keep the Blinding of Clinical Trials in Chinese Medicine. Modernization of Traditional Chinese Medicine and Materia Medical. 2014;16(12):2527\u201330.","journal-title":"Modernization of Traditional Chinese Medicine and Materia Medical"},{"issue":"7","key":"3539_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3736\/jcim20110703","volume":"9","author":"LP Hu","year":"2011","unstructured":"Hu LP, Bao XL, Wang Q. Methods and analysis of realizing randomized grouping. J Chin Integr Med. 2011;9(7):711\u20134.","journal-title":"J Chin Integr Med"},{"issue":"5","key":"3539_CR32","doi-asserted-by":"publisher","first-page":"e02446","DOI":"10.1128\/aac.02446-16","volume":"61","author":"A Dalhoff","year":"2017","unstructured":"Dalhoff A, Schubert S, Vente A. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections. Antimicrob Agents Chemother. 2017;61(5):e02446\u201316. \n                    https:\/\/doi.org\/10.1128\/aac.02446-16\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"3539_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006;68:318\u201323.","journal-title":"Urology."},{"key":"3539_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/nau.10099","volume":"22","author":"Y Homma","year":"2003","unstructured":"Homma Y, Yoshida M, Obara K, et al. Development and validity of the Overactive Bladder Symptom Score (OABSS) urodynamics. Neurourol Urodyn. 2003;22:105\u20138.","journal-title":"Neurourol Urodyn."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3539-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3539-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3539-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T19:13:00Z","timestamp":1595013180000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3539-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3539"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3539-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.75\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.75\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol has been approved by the Ethics Committee of the XiYuan Hospital, China Academy of Chinese Medical Sciences (2018XLA03l-3), the Longhua Hospital Shanghai University of Traditional Chinese Medicine (2018LCSY034), the Guangdong Provincial Hospital of Traditional Chinese Medicine (BF2018\u2013083-01), the Hubei Hospital of Traditional Chinese Medicine (SL2018-C19\u201301), the Affiliated hospital of Chengdu University of Traditional Chinese Medicine (2018KL-053), the Yunnan Provincial Hospital of Traditional Chinese Medicine (2018LLZ-014-NO.01). Based on the Declaration of Helsinki, written informed consent will be obtained from all study participants. Any modifications to the protocol that may impact the conduct of the study, the potential benefits to the patients, or patient safety will require a formal amendment to the protocol, which should be approved by the ethics committee prior to implementation. Protocol modifications will be communicated to all centers involved through regular meetings and telephone conversations. All staff will be notified, trained, and qualified before conducting the trial.All patient-related information including case reports, laboratory specimens, and evaluation forms will be kept strictly confidential. All records will be kept in a safe, locked place and secured with password-protected access systems. To protect confidentiality, identification information will be deleted from all study documents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent will be taken from all participants before their taking part in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}